Does desmopressin reduce the risjk of post kidney biopsy bleeding? Checkout the beautiful VA answering this practical question by NSMC faculty Dr Divya Bajpai.
Double Trouble: ddAVP and the Bleeding Biopsy
Microvascular inflammation of kidney allografts
Microvascular inflammation from the perspective of a real unicorn: donor-specific antibodies with negative antibody mediated rejection 🦄
Underestimating primary aldosteronism?
Should we screen all individuals with hypertension for primary aldosteronism?
First ADPKD KDIGO guidelines
Hard to summarize all ADPKD guidelines in just 10 posts, but here it is!
Primary Hyperaldosteronism: MRAs and adrenal vein sampling
Do mineralocorticoid receptor antagonists (MRAs) truly hinder the laboratory diagnosis of hyperaldosteronism?
SLEEP-HD: is trazodone better in insomnia than CBT?
This trial rebranded trazodone as “trazodont” in dialysis population
Metformin in advanced CKD
Metformin in stage 4 CKD? Catch-up here
Microvascular inflammation in kidney allografts - The Visual Abstract
What is the effect of microvascular inflammation on kidney allografts? Checkout the crisp VA by NSMC faculty Dr Divya Bajpai.
Kidney Allografts-Play With Fire, Get Burned
Metformina en la ERC avanzada
Un estudio observacional con emulación de ensayo aleatorizado en Escocia sugiere que mantener metformina en pacientes con ERC estadio 4 se asocia con mejor supervivencia y sin aumento de eventos cardiovasculares adversos mayores 🫀.
¿Estamos listos para replantear esta práctica?
Aquí te dejamos el resumen visual por Cristina Popa #NephJC
Metformin- Should I Stay or Should I Go
Metformin in Advanced CKD
Should we continue metformin in eGFR under 30 ml/min? The visual abstract by Cristina Popa summarizes the conclusions from the Scottish cohort using target trial methodology.
The first KDIGO ADPKD guideline
The KDIGO ADPKD guideline is a result of a decade of global collaboration between physicians, researchers, advocates, and patients. 240 pages summarized in only 2 pictures, made by Cristina Popa.
KDIGO 2025 ADPKD Guidelines Review
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
Obinutuzumab en Nefritis Lúpica: ¿Un Nuevo Horizonte?
El estudio REGENCY, un ensayo fase 3, doble ciego y controlado con placebo, evaluó la eficacia y seguridad de obinutuzumab en pacientes con nefritis lúpica activa. ¿Es realmente eficaz y seguro en la depleción de células B en LN?
🔥 Hoy en #NephJC analizamos cómo estos hallazgos impactarán el futuro del tratamiento en la nefritis lúpica. 🕘 Únete a la discusión a las 9 pm EST en BlueSky🦋!
REGENCY: A B-Cell Super Destroyer in Lupus
Obinutuzumab in lupus nephritis: The REGENCY Trial Visual Abstract
Is Obinutuzumab Effective and Safe in Active Lupus Nephritis? Check out the beautiful VA by NSMC Faculty Dr Divya Bajpai on the REGENCY Trial, answering the same.
¿Los ARMs dificultan la identificación del HAP unilateral en el MVA?
¿Usar o no los antagonistas del receptor de mineralocorticoides para el diagnóstico de HAP en el muestreo venoso adrenal? 🤔
💡 ¿Mito o realidad? ¡Vamos a descubrirlo juntos!
🗣️ Únete al chat y comparte tu opinión! #NephJC
Mineralocorticoid Receptor Blockade prior to Adrenal Venous Sampling for PA - The Visual Abstract
Do Mineralocorticoid Receptor Antagonists Preclude the Identification of Unilateral Primary Aldosteronism at Adrenal Venous Sampling?
Guidelines recommend withholding MRAs prior to PA subtyping by AVS. Is it worth the risk of hypokalemia and hypertension? NSMC Faculty Dr Divya Bajpai answers with a crisp VA